These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. [Current problems in etiotropic therapy of mycoses]. Buslaeva GN Antibiot Khimioter; 2001; 46(1):35-9. PubMed ID: 11221084 [No Abstract] [Full Text] [Related]
12. [Mycostatic activity of new nystatin and polyfungin derivatives against fungi isolated from patients with recurrent mycoses]. Kwaśniewska J Pol Tyg Lek; 1988 Dec; 43(49):1599-602. PubMed ID: 3255911 [No Abstract] [Full Text] [Related]
15. [Clinical comparative studies of the effectiveness of polyfungin and nystatin Polfa in the treatment of infections of the skin and mucous membranes caused by yeast-like fungi]. Bienias L; Ruszczak Z; Kurnatowska A; Kwaśniewska Przegl Dermatol; 1976; 63(5):673-8. PubMed ID: 794932 [No Abstract] [Full Text] [Related]
17. Clinical study on the dose-effect relationship of a nifuratel-nystatin combination in the treatment of vulvo-vaginal infections. Polatti F; Nappi RE; Brundu B; Fantuzzi M; Frisenda L Arzneimittelforschung; 2003; 53(10):730-7. PubMed ID: 14650366 [TBL] [Abstract][Full Text] [Related]
18. Clinical use of oral nystatin in the prevention of systemic candidosis in patients at particular risk. Schäfer-Korting M; Blechschmidt J; Korting HC Mycoses; 1996; 39(9-10):329-39. PubMed ID: 9009654 [TBL] [Abstract][Full Text] [Related]
19. Systemic antifungal agents. What is in the pipeline? Kauffman CA Drugs R D; 1999 Feb; 1(2):153-9. PubMed ID: 10566012 [TBL] [Abstract][Full Text] [Related]
20. [New antimicrobial drugs: an update]. Burgmann H Wien Med Wochenschr; 2003; 153(7-8):166-8. PubMed ID: 12764871 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]